The Impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on Prescribing Practices: An Analysis of Data From a Large Midwestern State

被引:26
作者
Berkowitz, Rachel L. [2 ]
Patel, Urvashi [1 ]
Ni, Quanhong [1 ]
Parks, Joseph J. [4 ]
Docherty, John P. [3 ]
机构
[1] Care Management Technol Inc, Outcomes Res Div, Morrisville, NC 27560 USA
[2] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[3] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA
[4] Missouri Dept Mental Hlth, Jefferson, AR USA
关键词
CHRONIC-SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; METABOLIC SYNDROME; POLICY; OLANZAPINE; RISPERIDONE; CHALLENGES; DIFFUSION; KNOWLEDGE; BENCH;
D O I
10.4088/JCP.10m06497
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a series of effectiveness trials. The results of these trials began publication in September 2005. Among other findings, these studies were interpreted to suggest that (1) second-generation antipsychotics might have fewer advantages over first-generation antipsychotics than had been generally thought; (2) among the agents assessed, olanzapine had the best efficacy outcome; and (3) after treatment failure with a second-generation antipsychotic, the most efficacious second-line medication is clozapine. To examine the actual impact on practice of these publications, we looked at change in physician prescribing behavior based on these 3 conclusions before and after publication of CATIE. Method: Rates of antipsychotic medication prescriptions to 51,459 patients with an ICD-9 code of 295 for schizophrenia were extracted from a Missouri Medicaid claims database. X-2 Tests were used to compare the rates of prescribing antipsychotic medications before and after each of 3 key CATIE publications (time 1 was September 2005, time 2 was December 2006, and time 3 was April 2006). Results: At all time points, we demonstrated a decrease in prescriptions by all prescribers for olanzapine (P<.0001). One year after time 1, we found an increase in prescriptions by all prescribers for aripiprazole (P<.0001). No statistically significant increases in clozapine prescribing were observed. Also, a small but statistically significant increase was seen in prescriptions of perphenazine (P<.02 at time 3). However, this increase occurred only for prescriptions written by psychiatrists and not other prescribers. Conclusions: We found some evidence in our sample that the publication of the results from CATIE had a small but statistically significant effect on prescribing habits of psychiatrists but not other physicians in our sample population. However, larger changes occurred in prescribing behavior that were largely unrelated to the CATIE trial. We propose a hypothesis to explain the direction of observed changes. J Clin Psychiatry 2012;73(4):498-503 (C) Copyright 2011 Physicians Postgraduate Press, Inc.
引用
收藏
页码:498 / 503
页数:6
相关论文
共 28 条
[1]  
Alméras N, 2004, J CLIN PSYCHIAT, V65, P557
[2]  
Berenson A, 2006, NY TIMES 1121
[3]   Obesity, diabetes, and the metabolic syndrome: New challenges in antipsychotic drug therapy [J].
Caballero, E .
CNS SPECTRUMS, 2003, 8 (11) :19-22
[4]   Why don't physicians follow clinical practice guidelines? A framewouk for improvement [J].
Cabana, MD ;
Rand, CS ;
Powe, NR ;
Wu, AW ;
Wilson, MH ;
Abboud, PAC ;
Rubin, HR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15) :1458-1465
[5]  
Citrome L, 2008, PSYCHIAT SERV, V59, P476, DOI 10.1176/ps.2008.59.5.476
[6]   Charting a Path From Comparative Effectiveness Funding to Improved Patient-Centered Health Care [J].
Conway, Patrick H. ;
Clancy, Carolyn .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (10) :985-986
[7]   Tardive dyskinesia and new antipsychotics [J].
Correll, Christoph U. ;
Schenk, Eva M. .
CURRENT OPINION IN PSYCHIATRY, 2008, 21 (02) :151-156
[8]   What Explains the Diffusion of Treatments for Mental Illness? [J].
Drake, Robert ;
Skinner, Jonathan ;
Goldman, Howard H. .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (11) :1385-1392
[9]  
Duckworth K, 2008, PSYCHIAT SERV, V59, P537, DOI 10.1176/ps.2008.59.5.537
[10]  
Fluckiger SL, 2006, EXP BIOL MED, V231, P1257